Experimental CAR-T therapy takes on Hard-to-Treat liver cancer

NCT ID NCT06757881

Ongoing Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new type of immune cell therapy called IL1RAP-targeting CAR-T cells in just 3 people with advanced liver cancer that has not responded to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Researchers will watch for side effects like cytokine release syndrome and measure how long the cells last in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IL1RAP-targeting CAR-T cells (a type of immune cell therapy)
What this could lead to: If it works, this could point toward a new treatment option for advanced liver cancer that has stopped responding to standard therapies.
What could go wrong: This is a very early, tiny phase 1 trial with only 3 people, focused on safety, not effectiveness. The therapy may cause serious side effects like cytokine release syndrome, and it may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC

Contacts and locations

Locations

Zhongshan Hospital Affiliated to Fudan University

Shanghai, Shanghai Municipality, 200000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.